PE20010741A1 - Derivados de piperazina como antagonistas de taquicininas - Google Patents
Derivados de piperazina como antagonistas de taquicininasInfo
- Publication number
- PE20010741A1 PE20010741A1 PE2000001068A PE0010682000A PE20010741A1 PE 20010741 A1 PE20010741 A1 PE 20010741A1 PE 2000001068 A PE2000001068 A PE 2000001068A PE 0010682000 A PE0010682000 A PE 0010682000A PE 20010741 A1 PE20010741 A1 PE 20010741A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- members
- tachycinins
- antagonists
- methyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/32—Alcohol-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/04—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Abstract
SE REFIERE A DERIVADOS DE PIPERAZINA DE FORMULA I, DONDE R ES HALOGENO, ALQUILO C1-C4; R1 ES H, ALQUILO C1-C4; R2 ES H, ALQUILO C1-C4, ALQUENILO C2-C6, CICLOALQUILO C3-C7; R1 Y R2 JUNTO CON N FORMAN UN HETEROCICLO DE 5-6 MIEMBROS; R3 ES TRIFLUOROMETILO, ALQUILO C1-C4, ALCOXILO C1-C4, TRIFLUOROMETOXI, HALOGENO; R4 ES H, (CH2)qR7, (CH2)rCO(CH2)pR7; R5 ES H, ALQUILO C1-C4, COR6; R6 ES H, OH, AMINO, METILAMINO, DIMETILAMINO, HETEROARILO DE 5 MIEMBROS CON 1-3 O, S, N; HETEROARILO DE 6 MIEMBROS CON 1-3 N; R7 ES H, OH, NR8R9; R8 Y R9 SON H, ALQUILO C1-C4 OPCIONALMENTE SUSTITUIDO POR OH, AMINO; R10 ES H, ALQUILO C1-C4; R10 Y R2 SON CICLOALQUILO C3-C7; m Y n SON 0-3; p Y r SON 0-4; q ES 1-4; CUANDO R1 Y R2 JUNTO CON N Y C FORMAN UN HETEROCICLO DE 5-6 MIEMBROS; i)m ES 1-2; ii)CUANDO m ES 1; R NO ES F; iii)CUANDO m ES 2, LOS DOS R NO SON F. SON COMPUESTOS PREFERIDOS (3,5-BIS-TRIFLUOROMETIL-BENCIL)METIL-AMIDA DEL ACIDO 2-(4-FLUORO-2-METIL-FENIL)-PIPERAZIN-1-CARBOXILICO, CLORHIDRATO DE (3,5-BIS-TRIFLUORO-BENCIL)-METIL-AMIDA DEL ACIDO 2-(S)-(4-FLUORO-2-METIL-FENIL)-4-(PIPERIN-4-CARBONIL)-PIPERAZINA-1-CARBOXILICO. TAMBIEN SE REFIERE A UN PROCEDIMIENTO PARA LA PREPARACION. LOS COMPUESTOS SON ANTAGONISTAS DE TAQUICININAS (SUSTANCIA P, NEUROCININAS) Y PUEDEN SER UTIL PARA EL TRATAMIENTO DE LA DEPRESION, ANSIEDAD, PANICO
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9923748.9A GB9923748D0 (en) | 1999-10-07 | 1999-10-07 | Chemical compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20010741A1 true PE20010741A1 (es) | 2001-07-18 |
Family
ID=10862304
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE2000001068A PE20010741A1 (es) | 1999-10-07 | 2000-10-06 | Derivados de piperazina como antagonistas de taquicininas |
Country Status (33)
Country | Link |
---|---|
US (6) | US6951861B1 (es) |
EP (3) | EP1218359B1 (es) |
JP (1) | JP4776844B2 (es) |
KR (2) | KR100817373B1 (es) |
CN (1) | CN100413850C (es) |
AR (2) | AR025975A1 (es) |
AT (3) | ATE407125T1 (es) |
AU (1) | AU768780B2 (es) |
BR (1) | BR0014541A (es) |
CA (1) | CA2386515C (es) |
CO (1) | CO5251467A1 (es) |
CY (2) | CY1110172T1 (es) |
CZ (1) | CZ302340B6 (es) |
DE (3) | DE60042501D1 (es) |
DK (3) | DK1218359T3 (es) |
ES (3) | ES2312917T3 (es) |
GB (1) | GB9923748D0 (es) |
HK (3) | HK1052506B (es) |
HU (1) | HUP0203136A3 (es) |
IL (2) | IL148964A0 (es) |
MX (1) | MXPA02003515A (es) |
MY (1) | MY130907A (es) |
NO (1) | NO323776B1 (es) |
NZ (2) | NZ518144A (es) |
PE (1) | PE20010741A1 (es) |
PL (1) | PL201191B1 (es) |
PT (3) | PT1218359E (es) |
SI (3) | SI1454901T1 (es) |
TN (1) | TNSN00194A1 (es) |
TR (1) | TR200200936T2 (es) |
TW (1) | TWI225485B (es) |
WO (1) | WO2001025219A2 (es) |
ZA (1) | ZA200202589B (es) |
Families Citing this family (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002537245A (ja) * | 1999-02-18 | 2002-11-05 | ノバルティス アクチエンゲゼルシャフト | 5−ht3レセプターアンタゴニストの使用 |
GB9923748D0 (en) * | 1999-10-07 | 1999-12-08 | Glaxo Group Ltd | Chemical compounds |
USRE39921E1 (en) | 1999-10-07 | 2007-11-13 | Smithkline Beecham Corporation | Chemical compounds |
AUPQ514600A0 (en) * | 2000-01-18 | 2000-02-10 | James Cook University | Brain injury treatment |
GB0003232D0 (en) * | 2000-02-11 | 2000-04-05 | Smithkline Beecham Plc | Novel composition |
GB0025354D0 (en) | 2000-10-17 | 2000-11-29 | Glaxo Group Ltd | Chemical compounds |
GB0108595D0 (en) | 2001-04-05 | 2001-05-23 | Glaxo Group Ltd | Chemical compounds |
GB0108594D0 (en) * | 2001-04-05 | 2001-05-23 | Glaxo Group Ltd | Chemical compounds |
US20030083345A1 (en) * | 2001-07-10 | 2003-05-01 | Torsten Hoffmann | Method of treatment and/or prevention of brain, spinal or nerve injury |
GB0119797D0 (en) * | 2001-08-14 | 2001-10-03 | Glaxo Group Ltd | Chemical compounds |
GB0124463D0 (en) | 2001-10-11 | 2001-12-05 | Smithkline Beecham Plc | Compounds |
GB0203020D0 (en) | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
GB0203022D0 (en) * | 2002-02-08 | 2002-03-27 | Glaxo Group Ltd | Chemical compounds |
US7482365B2 (en) | 2002-02-08 | 2009-01-27 | Glaxo Group Limited | Piperidylcarboxamide derivatives and their use in the treatment of tachykinin-mediated diseases |
DE10209145A1 (de) * | 2002-03-01 | 2003-09-04 | Bayer Cropscience Ag | Halogenbenzole |
AU2003243353A1 (en) * | 2002-05-29 | 2003-12-19 | The Regents Of The University Of California | Antagonizing nk1 receptors inhibits consumption of substances of abuse |
JP4079727B2 (ja) * | 2002-09-06 | 2008-04-23 | セントラル硝子株式会社 | 光学活性1−(フルオロ、トリフルオロメチルまたはトリフルオロメトキシ置換フェニル)アルキルアミンn−モノアルキル誘導体とその製造方法 |
WO2004067093A2 (en) * | 2003-01-27 | 2004-08-12 | Glaxo Group Limited | Nk1 receptor antagonists for the treatment of functional dyspepsia |
GB0308968D0 (en) * | 2003-04-17 | 2003-05-28 | Glaxo Group Ltd | Medicaments |
MXPA05013770A (es) * | 2003-06-19 | 2006-03-08 | Pfizer Prod Inc | Antagonista de neuroquinina 1. |
US20070142367A1 (en) * | 2003-11-10 | 2007-06-21 | Lundeen James E | Method and medicine for treating gastrointestinal disorder including fecal incontinence |
US20060148783A1 (en) * | 2003-11-10 | 2006-07-06 | Lundeen James E | Method and medicine for treating gastrointestinal disorder including fecal incontinence |
US20060148781A1 (en) * | 2003-11-10 | 2006-07-06 | Lundeen James E | Method and medicine for treating gastrointestinal disorder in a non-human mammal |
US20050113365A1 (en) * | 2003-11-10 | 2005-05-26 | Sir Isaac Newton Enterprises Llc | Method and medicine for treating gastrointestinal disorder including irritable bowel syndrome |
US20060148782A1 (en) * | 2003-11-10 | 2006-07-06 | Lundeen James E | Method and medicine for treating a mammal presenting urinary incontinence, urinary urgency, or both |
JPWO2005051912A1 (ja) * | 2003-11-28 | 2007-12-06 | 田辺三菱製薬株式会社 | ピペリジン化合物およびその製法 |
EP1705176A4 (en) * | 2004-01-14 | 2009-06-03 | Takeda Pharmaceutical | CARBOXYLAMIDE DERIVATIVE AND ITS USE |
TW200730494A (en) * | 2005-10-10 | 2007-08-16 | Glaxo Group Ltd | Novel compounds |
US7855218B2 (en) * | 2005-10-10 | 2010-12-21 | Convergence Pharmaceuticals Limited | Compounds |
US20100009983A1 (en) * | 2006-05-09 | 2010-01-14 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
JP4904945B2 (ja) | 2006-06-30 | 2012-03-28 | セントラル硝子株式会社 | 光学活性1−(フルオロ、トリフルオロメチルまたはトリフルオロメトキシ置換フェニル)アルキルアミンn−モノアルキル誘導体の製造方法 |
GB0621229D0 (en) * | 2006-10-20 | 2006-12-06 | Glaxo Group Ltd | Novel use |
EP2129381A1 (en) | 2007-01-24 | 2009-12-09 | Glaxo Group Limited | Pharmaceutical compositions comprising 3, 5-diamin0-6- (2, 3-dichl0phenyl) -l, 2, 4-triazine or r (-) -2, 4-diamino-5- (2, 3-dichlorophenyl) -6-fluoromethyl pyrimidine and an nk1 |
JP5510040B2 (ja) * | 2010-04-28 | 2014-06-04 | セントラル硝子株式会社 | 光学活性(r)−1−(4−フルオロフェニル)エチルアミンを得る光学分割 |
WO2012175434A1 (en) | 2011-06-20 | 2012-12-27 | Glaxo Group Limited | Pharmaceutical formulations comprising vestipitant |
ES2672099T3 (es) | 2011-07-04 | 2018-06-12 | Irbm - Science Park S.P.A. | Antagonistas del receptor NK-1 para el tratamiento de la neovascularización corneal |
KR20140122764A (ko) * | 2012-02-22 | 2014-10-20 | 레오 파마 에이/에스 | 신규한 뉴로키닌 1 수용체 길항제 화합물 |
WO2015024203A1 (en) * | 2013-08-20 | 2015-02-26 | Leo Pharma A/S | Novel neurokinin 1 receptor antagonist compounds ii |
ES2912881T3 (es) | 2014-12-23 | 2022-05-30 | Convergence Pharmaceuticals | Procedimiento para preparar derivados de alfa-carboxamida pirrolidina |
US10399949B2 (en) | 2015-12-07 | 2019-09-03 | Kissei Pharmaceutical Co., Ltd. | NK1 receptor antagonist |
AU2018251604B2 (en) | 2017-04-10 | 2022-04-14 | Chase Therapeutics Corporation | NK1-antagonist combination and method for treating synucleinopathies |
EP3645120A4 (en) | 2017-06-30 | 2021-03-24 | Chase Pharmaceuticals Corporation | NK-1 ANTAGONIST COMPOSITIONS AND METHODS OF USE IN THE TREATMENT OF DEPRESSION |
KR20200061381A (ko) | 2017-10-05 | 2020-06-02 | 바이오젠 인크. | 알파-카르복스아미드 피롤리딘 유도체를 제조하기 위한 공정 |
Family Cites Families (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4110327A (en) | 1974-05-09 | 1978-08-29 | Toyama Chemical Co., Ltd. | 2,3 Diketo-piperazinocarbonylamino alkanoic acids and derivatives |
US4112090A (en) | 1974-05-09 | 1978-09-05 | Toyama Chemical Co., Ltd. | Novel penicillins and cephalosporins and process for producing the same |
US4219554A (en) | 1974-05-09 | 1980-08-26 | Toyama Chemical Company, Limited | Novel penicillins and cephalosporins and process for producing same |
US4379152A (en) | 1974-05-09 | 1983-04-05 | Toyama Chemical Co., Ltd. | Cephalosporins |
US4087424A (en) | 1974-05-09 | 1978-05-02 | Toyama Chemical Co., Ltd. | Novel penicillins and cephalosporins and process for producing the same |
US4410522A (en) | 1974-05-09 | 1983-10-18 | Toyama Chemical Co., Ltd. | Cephalosporins |
US4327097A (en) | 1974-05-09 | 1982-04-27 | Toyama Chemical Co., Ltd. | Novel penicillins |
IL47168A (en) | 1974-05-09 | 1979-07-25 | Toyama Chemical Co Ltd | Mono or dioxo piperazino(thio)carbonylamino derivatives ofpenicillins and cephalosporins and process for producing the same |
NO154582C (no) * | 1978-10-20 | 1986-11-05 | Ferrosan Ab | Analogifremgangsmaate for fremstilling av terapeutisk aktive difenyl-dibutylpiperazinkarboksamider. |
JPS57118587A (en) | 1981-11-26 | 1982-07-23 | Toyama Chem Co Ltd | Novel penicillin |
US5028610A (en) | 1987-03-18 | 1991-07-02 | Sankyo Company Limited | N-benzhydryl-substituted heterocyclic derivatives, their preparation and their use |
GB8709666D0 (en) | 1987-04-23 | 1987-05-28 | Beecham Group Plc | Compounds |
GB8713061D0 (en) | 1987-06-04 | 1987-07-08 | Beecham Group Plc | Compounds |
US5109014A (en) | 1990-12-10 | 1992-04-28 | Jacobson Richard M | N-aryl-3-aryl-4-substituted-2,3,4,5-tetrahydro-1H-pyrazole-1-carboxamides |
SE9100860D0 (sv) | 1991-03-22 | 1991-03-22 | Kabi Pharmacia Ab | New use |
ES2149767T5 (es) | 1991-09-20 | 2005-06-16 | Glaxo Group Limited | Nuevo uso medico para antagonistas de taquiquininas. |
EP0545478A1 (en) | 1991-12-03 | 1993-06-09 | MERCK SHARP & DOHME LTD. | Heterocyclic compounds as tachykinin antagonists |
US5563127A (en) | 1993-03-24 | 1996-10-08 | The Dupont Merck Pharmaceutical Company | Boronic acid and ester inhibitors of thrombin |
US5348955A (en) | 1993-06-22 | 1994-09-20 | Merck & Co., Inc. | N,N-diacylpiperazines |
IL111730A (en) | 1993-11-29 | 1998-12-06 | Fujisawa Pharmaceutical Co | Piperazine derivatives, processes for their preparation and pharmaceutical preparations containing them |
TW385308B (en) | 1994-03-04 | 2000-03-21 | Merck & Co Inc | Prodrugs of morpholine tachykinin receptor antagonists |
US5464788A (en) | 1994-03-24 | 1995-11-07 | Merck & Co., Inc. | Tocolytic oxytocin receptor antagonists |
DE4425146A1 (de) | 1994-07-15 | 1996-01-18 | Basf Ag | Verwendung heterocyclischer Verbindungen |
AU3085895A (en) | 1994-07-26 | 1996-02-22 | Sankyo Company Limited | N-phenylated amide and urea derivatives |
DE19520499C2 (de) | 1994-09-17 | 2003-06-18 | Boehringer Ingelheim Kg | Neurokinin-Antagonisten, Verfahren zu ihrer Herstellung, diese Verbindungen enthaltende pharmazeutische Zusammensetzungen sowie ihre Verwendung |
US5696123A (en) | 1994-09-17 | 1997-12-09 | Boehringer Ingelheim Kg | Neurokinin antagonists |
US5998444A (en) | 1995-10-24 | 1999-12-07 | Zeneca Ltd. | Piperidinyl compounds as NK1 or NK2 antagonists |
DE69534213T2 (de) | 1994-10-25 | 2006-01-12 | Astrazeneca Ab | Therapeutisch wirksame Heterocyclen |
US5629322A (en) | 1994-11-15 | 1997-05-13 | Merck & Co., Inc. | Cyclic amidine analogs as inhibitors of nitric oxide synthase |
US5576317A (en) | 1994-12-09 | 1996-11-19 | Pfizer Inc. | NK-1 receptor antagonists and 5HT3 receptor antagonists for the treatment of emesis |
EE9700141A (et) | 1994-12-23 | 1997-12-15 | Dr. Karl Thomae Gmbh | Piperasiinderivaadid, neid sisaldavad ravimid, nende kasutamine ja valmistamise meetod |
US5700801A (en) | 1994-12-23 | 1997-12-23 | Karl Thomae, Gmbh | Piperazine derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them |
NZ321575A (en) | 1995-10-30 | 1999-05-28 | Janssen Pharmaceutica Nv | 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives |
DE19608665A1 (de) | 1996-03-06 | 1997-09-11 | Boehringer Ingelheim Kg | Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
US6057323A (en) | 1996-03-08 | 2000-05-02 | Adolor Corporation | Kappa agonist compounds pharmaceutical formulations and method of prevention and treatment of pruritus therewith |
US5859012A (en) | 1996-04-03 | 1999-01-12 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
WO1997036593A1 (en) * | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
WO1997036888A1 (en) | 1996-04-03 | 1997-10-09 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
AU707139B2 (en) | 1996-04-03 | 1999-07-01 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
AU3359697A (en) | 1996-07-08 | 1998-02-02 | Yamanouchi Pharmaceutical Co., Ltd. | Bone resorption inhibitors |
AU3716997A (en) * | 1996-07-17 | 1998-02-09 | Merck & Co., Inc. | Alteration of circadian rhythmicity with a tachykinin antagonist |
US6117855A (en) | 1996-10-07 | 2000-09-12 | Merck Sharp & Dohme Ltd. | Use of a NK-1 receptor antagonist and an antidepressant and/or an anti-anxiety agent |
US5929077A (en) | 1996-11-08 | 1999-07-27 | Leftheris; Katerina | Thioproline-containing inhibitors of farnesyl protein transferase |
US5977104A (en) | 1996-12-02 | 1999-11-02 | Merck Sharp & Dohme Ltd. | Use of NK-1 receptor antagonists for treating bipolar disorders |
JP2001504852A (ja) | 1996-12-02 | 2001-04-10 | メルク シヤープ エンド ドーム リミテツド | 双極性障害の治療のためのnk−1受容体拮抗薬の使用 |
US6114315A (en) | 1996-12-02 | 2000-09-05 | Merck Sharp & Dohme Ltd. | Use of NK-1 receptor antagonists for treating major depressive disorders with anxiety |
AUPO735997A0 (en) | 1997-06-17 | 1997-07-10 | Fujisawa Pharmaceutical Co., Ltd. | Piperazine derivatives |
EP1014984A1 (en) | 1997-08-27 | 2000-07-05 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
EP1034164B1 (en) | 1997-11-24 | 2004-05-19 | Merck & Co., Inc. | Substituted beta-alanine derivatives as cell adhesion inhibitors |
KR20010086104A (ko) * | 1998-12-14 | 2001-09-07 | 후지야마 아키라 | 피페라진 유도체 |
GB9923748D0 (en) * | 1999-10-07 | 1999-12-08 | Glaxo Group Ltd | Chemical compounds |
AU7788500A (en) * | 1999-10-25 | 2001-05-08 | Janssen Pharmaceutica N.V. | Use of substance p antagonists for influencing the circadian timing system |
GB0025354D0 (en) | 2000-10-17 | 2000-11-29 | Glaxo Group Ltd | Chemical compounds |
US20030022891A1 (en) | 2000-12-01 | 2003-01-30 | Anandan Palani | MCH antagonists and their use in the treatment of obesity |
MY141736A (en) | 2002-10-08 | 2010-06-15 | Elanco Animal Health Ireland | Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists |
-
1999
- 1999-10-07 GB GBGB9923748.9A patent/GB9923748D0/en not_active Ceased
-
2000
- 2000-10-05 EP EP00969414A patent/EP1218359B1/en not_active Expired - Lifetime
- 2000-10-05 DE DE60042501T patent/DE60042501D1/de not_active Expired - Lifetime
- 2000-10-05 BR BR0014541-6A patent/BR0014541A/pt not_active Application Discontinuation
- 2000-10-05 KR KR1020027004438A patent/KR100817373B1/ko not_active IP Right Cessation
- 2000-10-05 AU AU79139/00A patent/AU768780B2/en not_active Ceased
- 2000-10-05 EP EP04076632A patent/EP1460066B1/en not_active Expired - Lifetime
- 2000-10-05 DE DE60040176T patent/DE60040176D1/de not_active Expired - Lifetime
- 2000-10-05 NZ NZ518144A patent/NZ518144A/xx not_active IP Right Cessation
- 2000-10-05 PT PT00969414T patent/PT1218359E/pt unknown
- 2000-10-05 AT AT04076650T patent/ATE407125T1/de active
- 2000-10-05 DK DK00969414T patent/DK1218359T3/da active
- 2000-10-05 SI SI200031010T patent/SI1454901T1/sl unknown
- 2000-10-05 PT PT04076650T patent/PT1454901E/pt unknown
- 2000-10-05 NZ NZ531127A patent/NZ531127A/en not_active IP Right Cessation
- 2000-10-05 IL IL14896400A patent/IL148964A0/xx active IP Right Grant
- 2000-10-05 DE DE60012031T patent/DE60012031T2/de not_active Expired - Lifetime
- 2000-10-05 US US10/089,964 patent/US6951861B1/en not_active Expired - Lifetime
- 2000-10-05 KR KR1020077026231A patent/KR100857671B1/ko not_active IP Right Cessation
- 2000-10-05 WO PCT/EP2000/009722 patent/WO2001025219A2/en active IP Right Grant
- 2000-10-05 EP EP04076650A patent/EP1454901B1/en not_active Expired - Lifetime
- 2000-10-05 CN CNB008158606A patent/CN100413850C/zh not_active Expired - Fee Related
- 2000-10-05 AT AT00969414T patent/ATE270664T1/de active
- 2000-10-05 ES ES04076650T patent/ES2312917T3/es not_active Expired - Lifetime
- 2000-10-05 JP JP2001528165A patent/JP4776844B2/ja not_active Expired - Fee Related
- 2000-10-05 CZ CZ20021166A patent/CZ302340B6/cs not_active IP Right Cessation
- 2000-10-05 TR TR2002/00936T patent/TR200200936T2/xx unknown
- 2000-10-05 PT PT04076632T patent/PT1460066E/pt unknown
- 2000-10-05 CO CO00075822A patent/CO5251467A1/es active IP Right Grant
- 2000-10-05 PL PL356261A patent/PL201191B1/pl unknown
- 2000-10-05 AT AT04076632T patent/ATE435215T1/de active
- 2000-10-05 ES ES00969414T patent/ES2222927T3/es not_active Expired - Lifetime
- 2000-10-05 SI SI200031037T patent/SI1460066T1/sl unknown
- 2000-10-05 ES ES04076632T patent/ES2329130T3/es not_active Expired - Lifetime
- 2000-10-05 MY MYPI20004668A patent/MY130907A/en unknown
- 2000-10-05 SI SI200030492T patent/SI1218359T1/xx unknown
- 2000-10-05 HU HU0203136A patent/HUP0203136A3/hu unknown
- 2000-10-05 CA CA2386515A patent/CA2386515C/en not_active Expired - Lifetime
- 2000-10-05 MX MXPA02003515A patent/MXPA02003515A/es active IP Right Grant
- 2000-10-05 DK DK04076650T patent/DK1454901T3/da active
- 2000-10-05 DK DK04076632T patent/DK1460066T3/da active
- 2000-10-06 AR ARP000105284A patent/AR025975A1/es not_active Application Discontinuation
- 2000-10-06 PE PE2000001068A patent/PE20010741A1/es not_active Application Discontinuation
- 2000-10-06 TN TNTNSN00194A patent/TNSN00194A1/en unknown
- 2000-10-07 TW TW089121014A patent/TWI225485B/zh not_active IP Right Cessation
-
2002
- 2002-04-01 IL IL148964A patent/IL148964A/en not_active IP Right Cessation
- 2002-04-03 ZA ZA200202589A patent/ZA200202589B/en unknown
- 2002-04-05 NO NO20021637A patent/NO323776B1/no not_active IP Right Cessation
- 2002-07-03 US US10/190,170 patent/US6642240B2/en not_active Ceased
-
2003
- 2003-07-03 HK HK03104740.2A patent/HK1052506B/zh not_active IP Right Cessation
- 2003-08-08 US US10/637,825 patent/US7071196B2/en not_active Expired - Fee Related
-
2004
- 2004-05-04 US US10/838,838 patent/US20040209893A1/en not_active Abandoned
- 2004-11-06 HK HK04108748A patent/HK1065798A1/xx not_active IP Right Cessation
- 2004-12-01 HK HK04109454.6A patent/HK1066537A1/xx not_active IP Right Cessation
-
2006
- 2006-01-18 US US11/334,267 patent/US7345041B2/en not_active Expired - Fee Related
-
2007
- 2007-12-13 US US11/955,847 patent/US7625904B2/en not_active Expired - Fee Related
-
2008
- 2008-11-27 CY CY20081101376T patent/CY1110172T1/el unknown
-
2009
- 2009-09-18 CY CY20091100969T patent/CY1110104T1/el unknown
-
2010
- 2010-07-15 AR ARP100102567A patent/AR077414A2/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20010741A1 (es) | Derivados de piperazina como antagonistas de taquicininas | |
PE20001483A1 (es) | Acidos oxamicos y derivados como ligandos de receptores tiroideos | |
PE20221264A1 (es) | Inhibidores de egfr | |
PE20070528A1 (es) | Compuestos heterociclicos como ligandos del receptor vaniloide del subtipo 1 | |
RU2013138834A (ru) | N-[3-(5-амино-3,3а,7,7а-тетрагидро-1н-2,4-диокса-6-аза-инден-7-ил)-фенил]-амиды в качестве ингибиторов васе1 и(или) васе2 | |
PE20061150A1 (es) | Derivados de n-(n-sulfonilaminoarilmetil)ciclopropanocarboxamida sustituidos como antagonistas del receptor vainilloide tipo 1 (vdr1) | |
PE20010543A1 (es) | Derivados de purina como inhibidores de tirosincinasa syk | |
PE20080404A1 (es) | Derivados bencil-amino-piperidina como inhibidores de cetp | |
PE20050132A1 (es) | Piperazinas heterociclicas sustituidas | |
PE20020589A1 (es) | 5-espiropirimidin-2,4,6-triona como inhibidores de metaloproteinasas | |
PE20061156A1 (es) | Derivados de benzamida como agentes inhibidores del transportador de glicina | |
PE20010009A1 (es) | Derivados de fenil - y piridinilo como antagonistas del receptor de la neuroquinina 1 | |
PE20001467A1 (es) | Derivados de 4-fenilpiridina como antagonistas del receptor de neuroquinina | |
PE20050420A1 (es) | Fenacilo 2-hidroxi-3-diaminoalcanos | |
PE20070113A1 (es) | Derivados de quinolina y quinazolina como inhibidores de tirosinquinasas flt3 y trkb | |
PE20071080A1 (es) | Compuestos de pirimidinona biciclicos como inhibidores de la integrasa de hiv | |
AR035548A1 (es) | Compuestos organicos | |
PE20091621A1 (es) | Derivados de amina como moduladores de la actividad de tlr y composiciones que los contienen | |
PE20090441A1 (es) | DERIVADOS DE IMIDAZO[1,2-a]PIRIDIN-2-ILMETIL PIPERIDINA SUSTITUIDA | |
ME01089B (me) | Derivat benzimidazola i njegova upotreba kao antagonista receptora aii | |
RU2009148673A (ru) | Производные пиразинона и их применение для лечения легочных заболеваний | |
PE20081845A1 (es) | Nuevos derivados de aminopirimidina como inhibidores de plk1 | |
PE20010070A1 (es) | COMPUESTOS DE PIRIMIDINONA COMO INHIBIDORES DE LA ENZIMA Lp-PLA2 | |
PE20070069A1 (es) | Piperazin-piperidinas como antagonistas y agonistas del receptor 5-ht1a | |
HUP0204226A2 (en) | Quinazoline derivatives, pharmaceutical compositions containing them, their use and process for the preparation of the compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FD | Application declared void or lapsed |